Palvella Therapeutics
PVLA
41 hedge funds and large institutions have $7.24M invested in Palvella Therapeutics in 2024 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 10 increasing their positions, 7 reducing their positions, and 8 closing their positions.
43% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 7
0.01% less ownership
Funds ownership: 0.49% → 0.48% (-0.01%)
1% less capital invested
Capital invested by funds: $7.32M → $7.24M (-$80.8K)
11% less funds holding
Funds holding: 46 → 41 (-5)
63% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$63.5K |
| 2 |
Squarepoint
New York
|
+$25.4K |
| 3 |
STA
Summit Trail Advisors
New York
|
+$24.4K |
| 4 |
Prudential Financial
Newark,
New Jersey
|
+$19.2K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$7.95K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
1IA
1620 Investment Advisors
Plymouth,
Massachusetts
|
-$318K |
| 2 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
-$173K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$38.8K |
| 4 |
CM
CM Management
Gulf Breeze,
Florida
|
-$30.5K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$18.7K |
PVLA Hedge Fund Activity: Q1 2024 in Review
41 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Palvella Therapeutics (PVLA) for Q1 2024, worth a combined $7.24M — down 1.1% from $7.32M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of PVLA and 3 opened new positions — a net loss of 5 holders — while 7 trimmed existing stakes and 10 added.
The largest buyer was Renaissance Technologies, adding an estimated $63.5K. The largest seller was 1620 Investment Advisors, exiting entirely with an estimated $318K sold.
- 41 institutional investors held Palvella Therapeutics (PVLA) as of Q1 2024, down from 46 in Q4 2023.
- Funds reported $7.24M of Palvella Therapeutics stock for Q1 2024, down 1.1% quarter-over-quarter.
- 3 funds opened new Palvella Therapeutics positions in Q1 2024 and 8 closed out, a net change of -5 holders.
- The largest Palvella Therapeutics buyer in Q1 2024 was Renaissance Technologies, an estimated $63.5K added.
- The largest Palvella Therapeutics seller in Q1 2024 was 1620 Investment Advisors, an estimated $318K sold.
Based on aggregated 13F filings for Q1 2024.